disease genes may not invariably be pathogenic, none of the currently available splicing 23 prediction tools appear to be capable of reliably distinguishing those GT>GC variants that 24 generate wild-type transcripts from those that do not. Recently, SpliceAI, a novel deep 25 residual neural network tool, has been developed for splicing prediction. Methodologically 26 distinct from previous approaches that either rely on human-engineered features and/or 27 which focus on short nucleotide windows adjoining exon-intron boundaries, SpliceAI 28 assesses splicing determinants by evaluating 10,000 nucleotides of flanking contextual 29 sequence to predict the functional role in splicing of each position in the pre-mRNA 30 transcript. Herein, we evaluated the performance of SpliceAI in the context of three datasets 31 of GT>GC variants, all of which had been characterized functionally in terms of their impact 32 on mRNA splicing. The first two datasets refer to our recently described "in vivo" dataset of 33 45 disease-causing GT>GC variants and the "in vitro" dataset of 103 GT>GC substitutions.
34
The third dataset comprised 12 BRCA1 GT>GC variants that were recently analyzed by 35 saturation genome editing. We processed all GT>GC variants using the default settings of 36 SpliceAI. Comparison of the SpliceAI-predicted and experimentally obtained functional 37 impact assessments of the analyzed GT>GC variants revealed that although SpliceAI 38 performed rather better than other prediction tools, it was still far from perfect. A key issue is 39 that the impact of GT>GC (as well as GT>GA or +2T>A) variants that generated wild-type 40 transcripts represents a quantitative change that can vary from barely detectable to almost 41 full expression of wild-type transcripts, with wild-type transcripts often co-existing with 42 aberrantly spliced transcripts. Our findings highlight the challenges that we still face in 43 attempting to accurately identify splice-altering variants. 44 45 KEYWORDS 46 full-length gene splicing assay, GT>GC variant, human genetic disease, in silico splicing 47 prediction, in vitro functional analysis, mRNA splicing, SpliceAI, 5' splice site, +2T>C variant 48 49
INTRODUCTION 50
Technological advances in DNA sequencing have made whole exome sequencing and even 51 whole genome sequencing increasingly practicable, especially in the clinical setting. 52
However, our ability to accurately interpret the clinical relevance of genetic variants, 53 particularly those that are rare or even private, has so far been quite limited; this represents a 54 rate-limiting step in realizing the full potential of precision medicine (Lappalainen et classifications. For a perfect prediction, the coefficient is +1; a coefficient of 0 is no better 155 than random, and no correlation between observed and predicted yields -1 (Matthews, 156 1975) . A ROC curve illustrates the diagnostic specificity and sensitivity of a binary classifier 157 system as its discrimination threshold is varied; this enables the selection of an optimum 158 threshold value. To assess the difference between the diagonal and the ROC curve 159 obtained, the area under the ROC curve is measured (AUC). An AUC of 0.5 would be a 160 random prediction whilst a perfect predictor would score 1. ROC analysis was carried out 161 using the R-based web tool easyROC (Goksuluk et al., 2016) .
162
For the MCC test, a contingency table was derived from dataset 2 (Supplementary Table  163 S2) where a true positive is defined as a predicted splice altering substitution for which 164 FLGSA produced no transcript and a true negative is a substitution not predicted to alter 165 splicing and for which FLGSA produces transcript. 166 167 2.5.
Functional analysis of two GT-affecting variants 168
The functional impact of two newly engineered GT-affecting variants in the HESX1 gene 169
were analyzed by means of the cell culture-based FLGSA method as previously described 170 (Lin et al., 2019b The third dataset was obtained courtesy of a perusal of the literature (Table 3) consequences of all tested substitutions were actually evaluated in their natural genomic 235 sequence contexts. Of the ~4000 BRCA1 single nucleotide substitutions analyzed, 12 were 236 GT>GC substitutions. Of these 12 GT>GC substitutions, one was classified as "functional", 237 two were classified as "intermediate" and the remaining nine were classified as "non-238
functional" (Table 3) . Whereas "functional" and "intermediate" were interpreted as having 239 generated wild-type transcripts, "non-functional" was interpreted as having not generated any 240
wild-type transcripts (Lin et al., 2019a ). As such, 25% (n = 3) of these 12 BRCA1 GT>GC 241 substitutions generated wild-type transcripts, a proportion largely consistent with our 242 estimated 15-18% rate. Moreover, the BRCA1 GT>GC variant in intron 18 was shown to be 243 "functional", providing further support for our contention that GT>GC variants in human 244 disease genes may not invariably be pathogenic (Lin et al., 2019b ).
245
Taken together, the experimentally obtained functional assessments of the included 246
GC>GT variants or substitutions were considered to be of high quality and appropriate for the 247 intended study. 248 249
Selection and interpretation of SpliceAI Delta scores for analysis 250
We processed GT>GC variants using the default settings of SpliceAI as detailed in 251 https://pypi.org/project/spliceai/. SpliceAI provides Delta scores (ranging from 0 to 1) for each 252 variant, thereby providing a measure of their probability of altering splicing in terms of either 253 splice donor gain, splice donor loss, splice acceptor gain, and splice acceptor loss. SpliceAI 254 also provides Delta position that conveys information specifying the location where splicing 255 differs from normal relative to the position of the associated variant. Since the GT>GC 256 variants or substitutions under study invariably affected the +2 position of the canonical 5' 257 splice site GT dinucleotides (in the context of the specified mRNA reference sequence), we 258 focused our analysis exclusively on the Delta scores of donor loss although other scores may 259 provide clues as to the nature of the resulting aberrantly spliced transcripts of splice-altering 260 variants. Thus, only the SpliceAI-predicted Delta scores of donor loss for the studied GT>GC 261 variants or substitutions are provided in Supplementary Tables S1 and S2 as well as in  262  Tables 1-3 . Here, it is important to note two points. First, the previously studied GT>GC 263 events generated maximally 84% wild-type transcripts as compared to their wild-type GT 264 allele counterparts (Lin et al., 2019b) . In other words, all these variants were associated 265 minimally with a 16% functional loss. Therefore, strictly speaking, all these previously studied 266 GT>GC events can be defined as splice-altering. Second, in those cases of GT>GC events 267 that generated wild-type transcripts, the level of wild-type transcript varied from 1-84% (Lin et  268 al., 2019b). Intuitively, whether or not a GT>GC variant capable of generating wild-type 269 transcripts is pathogenic is likely to depend at least in part upon the level of the generated 270 wild-type transcripts. Taking these points into consideration, we shall use the SpliceAI Delta 271 score of donor loss as a proxy indicator of the probability of a given GT>GC variant being 272 able to generate wild-type transcripts; variants with a Delta score above a certain cutoff value 273 will be considered not to be capable of generating wild-type transcripts whereas variants with 274 a Delta score below the cutoff value will be considered as being capable of generating wild-275 type transcripts. 276 277
Encouraging findings from a quick survey of the three datasets of GT>GC variants 278
As mentioned in the Introduction, none of the four most popular splicing prediction tools, 279
SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer, were found to be able to 280 distinguish those GT>GC variants that generated wild-type transcripts from those that did not 281 (Lin et al., 2019b). As described below, a quick survey of SpliceAI-predicted scores yielded 282 encouraging results across all three datasets of GT>GC variants. 283
First, in the context of dataset 1, the level of variant allele-derived wild-type transcripts 284 associated with the seven disease-causing GT>GC variants was at most 15% of normal 285 (Table 1) . Although this low level increase in the generation of wild-type transcripts may 286 make prediction a daunting task, it is interesting to see that the two lowest Delta scores of 287 donor loss, 0.35 and 0.63, were observed in association with the two variants that generated 288 ~10% wild-type transcripts (Supplementary Table S1 ; Table 1 ). As for the second dataset (Supplementary Table S2 ), the four lowest Delta scores of 301 donor loss (i.e., 0, 0.03, 0.05 and 0.08) were all found in substitutions that generated wild-302 type transcripts; and 63% (n = 12) of the 19 substitutions that generated some wild-type 303 transcripts had a Delta score of <0.80 (Table 2) . As for the third dataset, the lowest Delta 304 score, 0.53, was observed in association with the only "functional" BRCA1 IVS18+2T>C 305 variant (Table 3) Table S3) to calculate values for the false positive rate, specificity, 319 sensitivity, accuracy and the Matthews correlation coefficient. These are summarized in 320 Table 4 , along with the AUC result obtained from the ROC analysis, the curve from which is 321 shown in Fig. 1 . 322
As can be seen from 33-84% of the variants that generated wild-type transcripts and 67-89% of the variants that 335 generated no wild-type transcripts were correctly predicted by SpliceAI (Table 5 ).
336
The poorest performance (43% (3/7) and 33% (1/3)) was observed with datasets 1 and 3 337 variants that generated wild-type transcripts (Table 5 ). In the context of the seven dataset 1 338 variants that generated wild-type transcripts (a qualitative property), the relatively poor 339 performance of 43% might be related to the fact that the functional impact of these GT>GC 340 variants actually manifested as rather small quantitative changes, generating between 1-15% 341 normal transcripts (Table 1) . This notwithstanding, it should be pointed out that the two 342 disease-causing variants that generated 10-15% wild-type transcripts, CAV3 c.114+2T>C 343 (Muller et al., 2006) and CD40LG c.346+2T>C (Seyama et al., 1998) , had Delta scores of 344 ≥0.9 (Table 1) ; and in each of these two cases, RT-PCR analysis was performed using 345 patient-derived and pathologically relevant tissue or cells. In short, it remains unclear why 346 some of the disease-causing variants that generated comparable levels of wild-type 347 transcripts were predicted to have low Delta scores (i.e., DMD c.8027+2T>C and SPINK1 348 c.194+2T>C) whereas others were predicted to have high Delta scores (i.e., CAV3 349 c.114+2T>C and CD40LG c.346+2T>C). In the context of dataset 3 substitutions that 350 generated wild-type transcripts, the precise levels of wild-type transcripts generated by the 351 two "intermediate" BRCA1 +2T>C substitutions (both had a Delta score of ≥0.93; Table 3 ) 352 were unknown.
353
As for variants that did not generate wild-type transcripts, an excellent correlation rate, 354 89%, was observed with the 38 such disease-causing variants. By contrast, the performance 355 in datasets 2 and 3 variants was much lower and almost identical (68% and 67%, 356 respectively; Table 5 ). A fundamental difference between dataset 1 variants and the latter 357 two dataset substitutions is that all of the former were previously published whilst almost all 358 of the latter were prospectively generated. Thus, it is tempting to speculate that for most of 359 the 38 disease-causing variants that did not generate wild-type transcripts, their functional 360 effects might have been 'seen' by SpliceAI during training, thereby leading to a higher 361 correlation rate.
362
In an attempt to further understand the poor performance of dataset 2 and 3 substitutions 363 that did not generate wild-type transcripts, we opted to use the corresponding +2T>A and 364 +2T>G substitutions as controls. The underlying premise was that, based upon current 365 knowledge, +2T>A and +2T>G variants should completely disrupt normal splicing and 366 consequently have high Delta scores in virtually all cases (see also section 3.6). Here it is 367 worth mentioning that we previously employed FLGSA to analyze the functional impact of 15 368 +2T>A substitutions and 18 +2T>G substitutions, none of which generated any wild-type 369 transcripts (Lin et al., 2019b) . We processed all corresponding +2T>A and +2T>G variants 370 by means of SpliceAI in the same way as for the +2T>C variants (during October 2019), the 371 resulting Delta scores for donor loss being provided in Tables 1-3 and Supplementary Tables  372  S1 and S2.  373 As shown in Supplementary Table S1 , all +2T>A and +2T>G variants corresponding to 374 the 45 disease-causing +2T>C variants had very high Delta scores, ranging from 0.92 to 1.
375
By contrast, 91% (n = 94) of the +2T>A and +2T>G variants corresponding to the 103 376 dataset 2 +2T>C substitutions had a Delta score of ≥0.85 (Supplementary Table S2 ). In other 377 words, nine of the 103 +2T sites were predicted to have a Delta score of <0.85 when 378 substituted by either A or G; and in these sites, the Delta scores are often identical for all 379 three possible substitutions (Table 6 ). One possible reason for lower than expected Delta 380 scores is provided in (Jaganathan et al., 2019); exons which undergo a substantial degree of 381 alternative splicing, defined as being between 10% and 90% exon inclusion averaged across 382 samples, tend towards intermediate scores (stated as between 0.35 and 0.8). We therefore 383 explored this possibility using the two sites for which all possible substitutions had the lowest 384 Delta scores (i.e., 0.59 and 0.3; Table 6 ) as examples. To this end, alternative transcripts of 385 the genes of interest were surveyed via https://www.ncbi.nlm.nih.gov/gene/.
386
All three possible single nucleotide substitutions in the RPL11 g.23695910T (IVS5+2T in 387 accordance with NM_000975.5) site had an identical Delta score of 0.59. RPL11 has two 388 transcripts, the other being NM_001199802.1. Nonetheless, the two transcripts have 389 common coding sequences from exons 3-6. Moreover, all three possible single nucleotide 390 substitutions in the NM_000975.5-defined RPL11 IVS5+2T site have been previously 391 subjected to FLGSA, invariably generating no wild-type transcripts (Lin et al., 2019b) . Taken  392 together, in this particular case, the lower than expected Delta scores cannot be adequately 393 explained by alternative splicing.
394
All three possible single nucleotide substitutions in the LY6G6F g.31708136T (IVS5+2T in 395 accordance with NM_001003693.1) site had a score of 0.3 (Table 6 ). NM_001003693.1-396 defined LY6G6F has sequence from exons 1 to 4 in common with NM_001353334.2-defined 397 LY6G6F-LY6G6D, which represents naturally occurring readthrough transcription between 398 the neighboring LY6G6F and LY6G6D genes on chromosome 6 (Supplementary Fig. S1 ). By 399 contrast, NM_001003693.1-defined exons 5 and 6 are spliced out in NM_001353334. Supplementary Fig. S1 ), may not affect gene 409 splicing at all. 410
Finally, let us turn our attention to the BRCA1 findings in relation to NM_007294.3 (Table  411 3). The lowest Delta score of donor loss in the context of +2T>A and +2T>G variants, 0.65, 412 was observed for all three possible SNVs in the BRCA1 IVS4+2T site. The next lowest score, 413 0.67, was observed for all three possible SNVs in the BRCA1 IVS5+2T site (Table 3 ). All six 414 of these variants have been analyzed using saturation genome editing and were invariably 415 classified as "non-functional" (Jaganathan et al., 2019) . Moreover, although BRCA1 has 416 multiple transcripts, these two introns are used by all transcripts (Supplementary Fig. S2 ).
417
Therefore, as in the abovementioned RPL11 case, these lower than expected Delta scores 418 cannot be adequately explained by alternative splicing. 419 420 3.6. Additional findings 421
We succeeded in analyzing two additional engineered GT-impacting substitutions in the 422 HESX1 gene, IVS2+2T>A (hg38# chr3:57198751A>T) and IVS3+2T>G (hg38# 423 chr3:57198389A>C), using the cell culture-based FLGSA method. Interestingly, the 424 IVS2+2T>A substitution generated both wild-type and aberrant transcripts whereas 425 IVS3+2T>G generated only aberrant transcripts (Fig. 2) . Moreover, two of the 12 BRCA1 426 +2T>A substitutions, IVS16+2T>A and IVS18+2T>A, were described as being "intermediate" 427 (Table 3) . Although no disease-causing +2T>A variants have been found to generate wild-428 type transcripts, GA has recently been ranked fourth in terms of its relative frequency among 429 the six noncanonical 5' splice sites identified by genome-wide RNA-seq analysis and splicing 430 reporter assays (Erkelenz et al., 2018) . However, of the three +2T>A substitutions that were 431 experimentally shown to generate some wild-type transcripts, two were predicted to have a 432
Delta score of >0.85, namely 0.93 for HESX1 IVS2+2T>A (Supplementary Table S2 ) and 433 0.98 for BRCA1 IVS18+2T>A (Table 3) . The other one, BRCA1 IVS16+2T>A, was predicted 434
to have a Delta score of 0.74; but an identical score was also predicted for BRCA1 435 IVS16+2T>C and IVS16+2T>G, both of which were classified as "non-functional" (Table 3) .
436
In short, SpliceAI appeared not to work as well for the +2T>A variants that generated wild-437 type transcripts as for the +2T>C variants that generated wild-type transcripts. Table 2 . Supplementary Table S1 and Table 1 . 
